Co-Diagnostics Reports Q3 2026 Results with Declining Operating Expenses and New Regulatory Submissions
Co-Diagnostics (CODX) reported its third quarter 2026 financial results, highlighted by a 12% decrease in operating expenses, which totaled approximately $6.2 million. The company is currently focused on executing key regulatory and platform milestones to drive future growth. CEO Dwight Egan confirmed that the company has two active regulatory submissions currently under review. Notably, the company outlined its tuberculosis (TB) submission for India, reporting high diagnostic performance metrics with approximately 97.3% sensitivity and 96% specificity.
Tickers: $CODX
Topics: earnings call product milestones regulatory filings
Read the full article at Seeking Alpha
Part of the story AlTi Global Reports Q3 2026 Results with Reduced Expenses and New $85 Million Credit Facility (4 articles)